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Abstract 
Background: The reimbursement of orphan drugs (OD) is an increasingly important for country policymakers, 
and still insufficiently understood, especially in Central and Eastern Europe. The aim of this research was to provide 
a comprehensive description of country-specific health technology assessment (HTA) policies as well as evaluate 
the percentage of HTA recommendations and reimbursement decisions for oncology OD. In addition, the study 
was designed to elucidate the impact of reimbursement of these drugs on the public budget and the agreement 
between HTA recommendations and reimbursement decisions in the analysed countries. A questionnaire survey 
was used to collect data on the reimbursement status, HTA recommendation, marketing authorisation, and public 
expenses on reimbursement in 2014, 2015, and 2016 for all oncology drugs with an orphan designation by the 
European Medicine Agency in 2017 in Bulgaria, Croatia, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, 
and Slovakia. The agreement between the HTA recommendation and reimbursement status was assessed using the 
kappa coefficient. The Pearson’s correlation was used to analyse the relationship between gross domestic product 
(GDP) and GDP per capita and reimbursement expenses.
Results: A total of 36 drugs were analysed (25% conditionally approved; 5.56% approved under exceptional 
circumstances). The share of reimbursed drugs ranged from 11.11% in Latvia to 41.67% in Poland. The highest share 
of positive recommendations was observed for Bulgaria and Estonia (36.11%), and the lowest, for Latvia (11.11%). The 
agreement varied from 0.4 for Poland to 1 for Latvia, Hungary, and Slovakia. Expenses were correlated with GDP (0.95 
[0.81–0.99]), and not with GDP per capita (0.54 [− 0.136 to 0.873]). Expenses per capita were not correlated with GDP 
per capita (0.52 [− 0.15 to 0.87]).
Conclusions: In Hungary, Latvia, and Slovakia, a positive recommendation was associated with a reimbursement, 
and a negative one, with the lack of reimbursement. The reimbursement of oncology OD is associated with a growing 
burden for public budget, and the expenses are correlated with the total GDP. The highest share of drugs with any 
recommendation was observed in Poland, and the lowest, in Latvia and Romania. The share of reimbursed drugs was 
the lowest in Latvia and the highest in Poland.
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Background
Rare diseases mostly include inherited life-threatening 
or chronically debilitating diseases that affect fewer 
than 5 of 10,000 people, according to the definition 
developed by the European Medicines Agency (EMA). 
Oncological diseases constitute around one-third of 
rare diseases and include, for example, lymphoblastic 
leukaemia, CD30 + Hodgkin lymphoma, or advanced 
soft tissue sarcoma [1–5]. The reimbursement of those 
drugs—called oncology orphan drugs—is the main 
way of making them accessible for patients with rare 
oncological diseases.
The EMA approves orphan drugs through a centralised 
procedure and issues the orphan designation; however, 
the status for particular drugs varies between countries. 
Orphan drugs can be approved conditionally (if the 
required clinical data regarding, for example, safety and 
efficacy are not yet available but will become available 
within a specified period of time) or under exceptional 
circumstances (if the required data regarding, for 
example, safety will never be accessible, for example, due 
to ethical concerns) [6, 7].
Recommendations and the final reimbursement 
decisions made by health technology assessment 
(HTA) agencies in specific countries are particularly 
interesting for decision-makers in Central and Eastern 
Europe (CEE) because orphan drugs, in general, seem 
to be one of the most expensive pharmaceuticals [8]. 
It is becoming increasingly popular in CEE countries 
to implement special regulations regarding the 
reimbursement of orphan drugs, which affects not only 
the decision-making process but also the procedures of 
developing HTA recommendations and requirements 
[5]. The reimbursement of orphan drugs is the main 
determinant of patients’ access to innovative therapies, 
with the better availability of treatments in western 
European countries, as shown by German and French 
research [5, 14]. However, no sub-analysis for oncology 
orphan drugs was performed in relation to the CEE 
countries which are characterised by limited access to 
orphan biotechnological drugs, with Macedonia and 
Estonia having only one drug reimbursed, followed 
by Romania and Serbia with two drugs reimbursed, 
Bulgaria with three drugs reimbursed, Slovakia with 
four drugs reimbursed, and Croatia with seven drugs 
reimbursed [16].
To fill the knowledge gap, we aimed to 
comprehensively review the process of developing 
the recommendations based on HTA practices in 
these countries as well as to assess and compare 
the percentage of HTA recommendations and 
reimbursement status for oncology orphan drugs 
in selected CEE countries. In addition, we aimed to 
assess an agreement between recommendations and 
reimbursement status within the CEE countries for all 
orphan drugs that were assessed in selected countries, 
as this would provide information on relations between 
HTA assessment and the final reimbursement decision. 
Finally, we aimed to evaluate the expenditures from 
the public budget on the reimbursement of oncology 
orphan drugs over the period of 3 years, from 2014 to 
2016.
Results
We analysed 36 oncology drugs with orphan designation 
in 2017. Nine of them (25%) received conditional 
approval by the EMA and only 2 (5.56%) were approved 
under exceptional circumstances (Table 1).
Recommendations and reimbursement status
Of all analysed countries, the highest share of positive 
recommendations was observed for Bulgaria and Estonia 
and the lowest, for Latvia. Negative recommendations 
were issued only in Hungary, Latvia, Poland, and 
Slovakia. The remaining countries issued only positive 
recommendations or no recommendation at all, which 
was due to specific regulations in those countries 
(Table 2).
The share of reimbursed drugs ranged from 11.11% 
in Latvia to 41.67% in Poland, with an average value of 
28.89% (Table 2).
Recommendations and reimbursement status 
in the context of the type of authorisation
The share of positive recommendations among 
conditionally approved drugs ranged from 0% in 
Czechia, Lithuania, and Slovakia to 22.22% in Bulgaria, 
Estonia, Hungary, and Poland. Considering exceptional 
circumstances, the share of positive recommendations 
ranged from 0% in Croatia, Estonia, Latvia, Lithuania, 
and Slovakia to 50% in Bulgaria, Czechia, Hungary, 
Poland, and Romania. Among drugs with no additional 
approval conditions, the lowest share of positive 
recommendations was observed in Latvia (12%), and the 
highest, in Estonia (44%) (Table 2).
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Table 2 Share of positive recommendations and reimbursement decisions in analysed countries with respect to the type 
of approval
Unconditional means that neither conditional approval nor exceptional circumstances were granted
Country Approval type Recommendation Reimbursement Total
Positive Negative No recommendation Reimbursed Not reimbursed
Bulgaria Conditional approval 2 (22.22%) 0 (0%) 7 (77.78%) 2 (22.22%) 7 (77.78%) 9
Exceptional circumstances 1 (50%) 0 (0%) 1 (50%) 1 (50%) 1 (50%) 2
Unconditional 10 (40%) 0 (0%) 15 (60%) 10 (40%) 15 (60%) 25
Total 13 (36.11%) 0 (0%) 23 (63.89%) 13 (36.11%) 23 (63.89%) 36
Croatia Conditional approval 1 (11.11%) 0 (0%) 8 (88.89%) 2 (22.22%) 7 (77.78%) 9
Exceptional circumstances 0 (0%) 0 (0%) 2 (100%) 0 (0%) 2 (100%) 2
Unconditional 9 (36%) 0 (0%) 16 (64%) 6 (24%) 19 (76%) 25
Total 10 (27.78%) 0 (0%) 26 (72.22%) 8 (22.22%) 28 (77.78%) 36
Czechia Conditional approval 0 (0%) 0 (0%) 9 (100%) 0 (0%) 9 (100%) 9
Exceptional circumstances 1 (50%) 0 (0%) 1 (50%) 0 (0%) 2 (100%) 2
Unconditional 10 (40%) 0 (0%) 15 (60%) 10 (40%) 15 (60%) 25
Total 11 (30.56%) 0 (0%) 25 (69.44%) 10 (27.78%) 26 (72.22%) 36
Estonia Conditional approval 2 (22.22%) 0 (0%) 7 (77.78%) 2 (22.22%) 7 (77.78%) 9
Exceptional circumstances 0 (0%) 0 (0%) 2 (100%) 0 (0%) 2 (100%) 2
Unconditional 11 (44%) 0 (0%) 14 (56%) 11 (44%) 14 (56%) 25
Total 13 (36.11%) 0 (0%) 23 (63.89%) 13 (36.11%) 23 (63.89%) 36
Hungary Conditional approval 2 (22.22%) 1 (11.11%) 6 (66.67%) 2 (22.22%) 7 (77.78%) 9
Exceptional circumstances 1 (50%) 0 (0%) 1 (50%) 1 (50%) 1 (50%) 2
Unconditional 9 (36%) 4 (16%) 12 (48%) 9 (36%) 16 (64%) 25
Total 12 (33.33%) 5 (13.89%) 19 (52.78%) 12 (33.33%) 24 (66.67%) 36
Latvia Conditional approval 1 (11.11%) 0 (0%) 8 (88.89%) 1 (11.11%) 8 (88.89%) 9
Exceptional circumstances 0 (0%) 1 (50%) 1 (50%) 0 (0%) 2 (100%) 2
Unconditional 3 (12%) 3 (12%) 19 (76%) 3 (12%) 22 (88%) 25
Total 4 (11.11%) 4 (11.11%) 28 (77.78%) 4 (11.11%) 32 (88.89%) 36
Lithuania Conditional approval 0 (0%) 0 (0%) 9 (100%) 0 (0%) 9 (100%) 9
Exceptional circumstances 0 (0%) 0 (0%) 2 (100%) 0 (0%) 2 (100%) 2
Unconditional 10 (40%) 0 (0%) 15 (60%) 10 (40%) 15 (60%) 25
Total 10 (27.78%) 0 (0%) 26 (72.22%) 10 (27.78%) 26 (72.22%) 36
Poland Conditional approval 2 (22.22%) 3 (33.33%) 4 (44.44%) 2 (22.22%) 7 (77.78%) 9
Exceptional circumstances 1 (50%) 0 (0%) 1 (50%) 1 (50%) 1 (50%) 2
Unconditional 8 (32%) 9 (36%) 8 (32%) 12 (48%) 13 (52%) 25
Total 11 (30.56%) 12 (33.33%) 13 (36.11%) 15 (41.67%) 21 (58.33%) 36
Romania Conditional approval 1 (11.11%) 0 (0%) 8 (88.89%) 1 (11.11%) 8 (88.89%) 9
Exceptional circumstances 1 (50%) 0 (0%) 1 (50%) 1 (50%) 1 (50%) 2
Unconditional 6 (24%) 0 (0%) 19 (76%) 7 (28%) 18 (72%) 25
Total 8 (22.22%) 0 (0%) 28 (77.78%) 9 (25%) 27 (75%) 36
Slovakia Conditional approval 0 (0%) 1 (11.11%) 8 (88.89%) 0 (0%) 9 (100%) 9
Exceptional circumstances 0 (0%) 0 (0%) 2 (100%) 0 (0%) 2 (100%) 2
Unconditional 10 (40%) 2 (8%) 13 (52%) 10 (40%) 15 (60%) 25
Total 10 (27.78%) 3 (8.33%) 23 (63.89%) 10 (27.78%) 26 (72.22%) 36
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Agreement between recommendations 
and reimbursement status
In Hungary, of all 36 analysed drugs, 17 had both a 
recommendation and reimbursement decision issued. 
All drugs with a negative recommendation were not 
reimbursed and all drugs with a positive recommendation 
were reimbursed, resulting in perfect agreement with a 
kappa coefficient of 1 [95% CI 1–1]. A similar situation 
was observed in Latvia where of all 36 analysed drugs 8 
had both a recommendation and reimbursement status 
available. All 4 drugs with a negative recommendation 
received no reimbursement, and 4 drugs with a positive 
recommendation received reimbursement, resulting 
in perfect agreement with a kappa coefficient of 1 [95% 
CI 1–1]. Slovakia demonstrated perfect agreement 
(kappa coefficient of 1; 95% CI 1–1) due to all 10 drugs 
with a positive recommendation being reimbursed and 
all 3 drugs with a negative recommendation not being 
reimbursed. However, it was different in Poland where 23 
out of 36 drugs were analysed and the kappa coefficient 
was 0.4 [95% CI 0.04–0.76]. This is because out of 11 
drugs with a positive recommendation 2 did not receive 
reimbursement, and out of 12 drugs with a negative 
recommendation, 5 were finally reimbursed.
For the purpose of the additional analysis (i.e. 
sensitivity analysis), the lack of HTA recommendation 
was treated as the third category (in addition to positive 
and negative recommendations), which allowed for 
the calculation of weighted kappa coefficients for all 
countries, with the same set of drugs analysed in each 
country. The sensitivity analysis revealed that the 
agreement was 0.42 [95% CI 0.33–0.53] for Bulgaria, 0.14 
[95% CI 0.02–0.27] for Croatia, 0.35 [95% CI 0.23–0.47] 
for Czechia, 0.42 [95% CI 0.31–0.53] for Estonia, 0.46 
[95% CI 0.33–0.58] for Hungary, 0.20 [95% CI 0.05–0.35] 
for Latvia, 0.36 [95% CI 0.24–0.48] for Lithuania, 0.30 
[95% CI 0.13–0.46] for Poland, 0.29 [95% CI 0.16–0.42] 
for Romania and 0.39 [95% CI 0.26–0.51] for Slovakia.
Public payer expenses for reimbursement 
of analysed orphan drugs
Total expenditures from the public budget on the 
reimbursement of oncology orphan drugs varied between 
countries and years. The expenditures ranged from 
almost 850 thousand euro in 2014 in Latvia to almost 75 
million euro in 2016 in Poland. In all analysed countries, 
total expenses increased from 10% in Estonia to 243% 
in Lithuania between the years 2014 and 2016, with an 
average increase of 68%, as compared with an increase of 
only 8.5% in GDP and 9.3% in GDP per capita (Table 3).
Total expenditures on the reimbursement of analysed 
drugs were highly correlated with the total GDP in all 
countries, with a Pearson’s correlation coefficient of 0.961 
[95% CI 0.838–0.99] in 2014, 0.96 [95% CI 0.836–0.99] 
in 2015, 0.93 [95% CI 0.72–0.98] in 2016, and an average 
coefficient of 0.95 [95% CI 0.81–0.99]. All correlations 
were significant, with p-values of less than 0.0001 (Fig. 1).
No significant correlations were observed for GDP 
per capita (Pearson’s correlation coefficient: − 0.07 
[95% CI − 0.67 to 0.59] in 2014, − 0.01 [95% CI − 0.64 
to 0.62] in 2015, − 0.06 [95% CI − 0.66 to 0.59] in 2016, 
and an average of − 0.04 [95% CI − 0.66 to 0.6]) (Fig. 2). 
Moderate, non-significant correlations were observed 
between GDP per capita and total expenditures per 
capita with values of 0.5048 [95% CI − 0.1830 to 0.8608; 
p = 0.14) in 2014, 0.5427 [95% CI − 0.1320 to 0.8738; 
p = 0.11) in 2015, 0.4923 [95% CI − 0.1991 to 0.8564; 
p = 0.15) in 2016, and an average coefficient of 0.5206 
[95% CI − 0.1522 to 0.8663; p = 0.12) (Fig. 3). Moreover, 
no significant correlations were observed when analysing 
the share of reimbursed drugs (Pearson’s correlation 
coefficient: 0.536 [95% CI − 0.141 to 0.872] in 2014, 0.54 
[95% CI − 0.136 to 0.873] in 2015, 0.536 [95% CI − 0.141 
to 0.872] in 2016, and an average of 0.54 [95% CI − 0.136 
to 0.873]). No correlation between GDP and the share 
of reimbursed orphan drugs was observed for analysed 
countries [12].
Recommendations and HTA policy in analysed 
countries
In Bulgaria, during the time of the observation, 
recommendations on the reimbursement of a specific 
orphan drug are issued by the HTA Commission, the 
situation was then updated and now the National 
council of pricing and reimbursement is performing the 
procedure for HTA evaluation, pricing and inclusion 
in to the PDL. A positive recommendation from the 
Table 3 Total expenditures from  public budget 
on the reimbursement of oncology orphan drugs







Bulgaria 11 13 16
Croatia 9 11 15
Czechia 27 36 44
Estonia 4 5 5
Hungary 18 27 41
Latvia 1 1 1
Lithuania 2 3 4
Poland 57 67 75
Romania 24 27 31
Slovakia 23 27 33
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commission is one of the conditions for reimbursement. 
The final decision on reimbursement and inclusion in 
the Positive Drug List is made by the National Council 
for Prices and Reimbursement of Medicinal Products. 
Another obligatory condition is to sign a managed entry 
agreement with the payer. Only the positive reports of the 
commission are published (on the website of the National 
Centre of Public Health and Analyses, along with full 
HTA reports). Orphan drugs to be reimbursed do not 
necessarily need to show cost-effectiveness, the additional 
Fig. 1 Correlation between total gross domestic product (GDP) and total public expenditures on the reimbursement of analysed drugs in 2014, 
2015, and 2016, as well as an average value
Fig. 2 Correlation between total gross domestic product per capita (GDP per capita) and total public expenditures on the reimbursement of 
analysed drugs in 2014, 2015, and 2016, as well as an average value
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assessments are also considered. HTA requirements 
include the results from clinical, pharmacoeconomic, and 
budget impact analyses, as well as ethical considerations. 
There is no need for an additional analysis. Bulgarian 
regulation on HTA necessitate for the applying products 
not to have negative HTA evaluation in UK, or France, 
or Germany. However nowadays it has changed and it is 
necessitate to have positive evaluation in UK, or France, 
or Germany, or Sweden (Table 4).
In Croatia, most of the recommendations for orphan 
drugs are solved by the Croatian Health Insurance Fund 
(CHIF)’s Committee for Medicines, but HTA Agency 
can make a recommendation on the reimbursement 
of a specific orphan drug on special request. A positive 
recommendation of the CHIF’s Committee for Medicines 
means that the orphan drug will definitely obtain 
reimbursement. The CHIF’s list of the reimbursed drugs 
is publicly available, but it does not explain the procedure 
itself. The recommendations for reimbursement are 
internal documents of the CHIF. HTA requirements 
include results from sensitivity analysis, modelling, 
subgroup analysis, and others (Table 4).
In Czechia, the State Institute for Drug Control (SUKL) 
acts as an advisory and a decision-making body. The 
recommendations are published on the website, along 
with administrative files that can be accessed only with an 
electronic signature. All recommendations and files are 
available only in Czech. In most situations, orphan drugs 
must show cost-effectiveness in order to be reimbursed, 
apart from highly innovative medicinal products. In 
general, the same reimbursement rules apply to both 
orphan and non-orphan drugs and include acceptable 
efficacy, safety profile, and HTA requirements (Table 4).
In Estonia, there is no separate HTA advisory body; 
however, in some situations, the Ministry of Social Affairs 
and Estonian Health Insurance Fund ask the University 
of Tartu for advice, as it has a working group that writes 
HTA reports on special request. The reimbursement 
decision depends primarily on the budget impact, and 
a positive recommendation by the University of Tartu 
(if requested) does not guarantee reimbursement. The 
recommendations are published quarterly at the website 
of the Ministry of Social Affairs, or once a year at the 
website of the Health Insurance Fund for health care 
services. The HTA requirements for orphan drugs are the 
same as for other drugs (Table 4).
In Hungary, several advisory bodies make HTA 
recommendations, including the National Institute 
of Health Insurance Fund Management, Department 
of Health Technology Assessment, HTA Committee, 
Ministry of Human Capacities, and National 
Pharmaceutical Therapeutic Committee. A positive 
recommendation by any of those bodies does not 
always translate into a positive reimbursement decision, 
because the reimbursement process is more complex. 
For new active substances or a new indication, it is 
necessary to amend the reimbursement law. Only the 
final decisions, but not recommendations, are published. 
Fig. 3 Correlation between total gross domestic product per capita (GDP per capita) and total public expenditures on the reimbursement of 
analysed drugs per capita in 2014, 2015, and 2016, as well as an average value
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The most important criteria for reimbursement are 
cost-effectiveness, equity, budget impact, the severity 
of illness, and efficacy. The acceptable safety profile is 
analysed before the marketing authorisation by the EMA 
or the National Institute of Pharmacy and Nutrition. The 
evaluation by an HTA department includes the analysis 
of the safety profile (e.g. considering real-world evidence, 
among other important factors). There are no separate 
HTA requirements for orphan drugs (Table 4).
In Latvia, decisions on reimbursement are made by 
the National Health Service (NHS). Internal National 
Health Service bodies make recommendations, which 
are published on the website. Inclusion in a positive drug 
list is possible if the drug is cost-effective, has no budget 
impact, or if additional financial resources are allocated 
for this aim (Table 4).
In Lithuania, there is no stand alone HTA body. 
However, therapeutic value of medicines applied for 
reimbursement is assessed by State Medicines Control 
Agency, whereas economic evaluation is carried out by 
the Pharmaceutical department of the Ministry of Health. 
Decision on reimbursement takes Reimbursement 
Commission of the Ministry of Health taking into 
account therapeutic and economical evaluation. 
Assessment reports of therapeutic value and economical 
evaluation as well as protocols of the meetings of the 
reimbursement commission are publicly available on 
the website of the Ministry of Health (in Lithuanian 
language). Drugs are reimbursed if they are included in 
the reimbursement list. Each drug to be included in a 
positive drug list must show cost-effectiveness, except 
for orphan drugs for ultra-rare diseases. Conditional 
approval or approval under exceptional circumstances 
are not specifically taken into account. Decision is made 
on evidence of clinical value (Table 4).
In Poland, there are 2 advisory bodies: the Agency 
for Health Technology Assessment and Tariff System 
(AOTMiT) and within AOTMiT the Transparency 
Council. The AOTMiT makes positive or negative 
recommendations. The Transparency Council issues 
opinions to the President of the AOTMiT that can also 
be positive or negative. Neither positive recommendation 
by AOTMiT nor TC guarantees reimbursement. All 
recommendations and opinions are publicly available at 
the AOTMiT’s website (Table 4).
In Romania, the National Agency for Medicines 
and Medical Devices is an advisory body in the 
reimbursement decision-making process. A drug is 
reimbursed following the positive advice of the agency; 
however, new drugs that require additional funding 
are subject to volume price negotiations. Orphan drugs 
that are included in a national therapeutic programme 
are fully reimbursed. Once a drug receives a positive 
recommendation, it must be officially included in the 
list and the publicly available guideline for a specified 
disease is modified. Then, the drug is reimbursed by the 
Ministry of Health and National Agency for Medicines 
and Medical Devices (NHIH) (Table 4).
The Slovak Ministry of Health established the 
Reimbursement (or Categorisation) Committee to act 
as its advisory body with regards to reimbursement. The 
committee is supported by different advisory working 
groups, a medical board (assessing the effectiveness, 
safety, and importance of the medicine), and the Working 
Group for Pharmacoeconomics, Clinical Outcomes 
and Health Technology Assessment of the Ministry 
of Health. The recommendation of the Categorisation 
Committee can be overruled by the Minister of Health. 
Recommendations are publicly available at the website of 
the ministry. Orphan drugs must show cost-effectiveness; 
however, the thresholds were not applicable for orphan 
drugs indicated in the therapy of rare diseases with a 
prevalence of less than 1:100,000 in Slovakia. Based 
on the evaluation of the drug’s effectiveness, safety, 
and importance as well as economic benefits, the 
Categorisation Committee determines its therapeutic 
and social value. Again, the thresholds were not 
applicable for orphan drugs indicated in the therapy of 
rare diseases with a prevalence of less than 1:100,000. The 
threshold prevalence was updated in 2018 to 1:50,000 
(Table 4).
Discussion
The study revealed that most analysed countries 
implemented some sort of an HTA process in their 
reimbursement decision-making process and in 
the majority of these countries, publicly available 
reimbursement recommendations were used.
In general, in all analysed countries orphan drugs are 
required to be cost-effective, present an acceptable safety 
profile and high enough efficacy however different rules 
are applied when making final decision. Although the 
recommendations do not easily translate into positive 
reimbursement decision the observed kappa coefficients 
were high. The study showed that, in most countries, 
HTA recommendations are issued together with positive 
reimbursement decisions, which translates into a perfect 
agreement of 1. The exception was Poland, where the 
kappa coefficient was 0.4, mainly because almost 42% 
of drugs with a negative recommendation were finally 
reimbursed. Importantly, once the reimbursement 
recommendation is issued by the AOTMiT in Poland, the 
Marketing Authorisation Holder can enter negotiations 
with the Ministry of Health. This often results in reducing 
the cost of the drugs or introducing risk-sharing schemes, 
which has a direct impact on reimbursement. Unlike the 
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recommendations by the AOTMiT, the negotiations are 
not publicly available and thus cannot be analysed.
In addition, we assessed the burden of costs generated 
by the reimbursement of the analysed oncology drugs 
in the years 2014–2016 on the public payer budget. 
An average increase in public expenditures on the 
reimbursement was 68%, as compared with an increase of 
only 8.5% in the total GDP and of 9.3% in GDP per capita. 
The factors influencing the increase could be associated 
with an increased number of reimbursed drugs, subject 
that was covered extensively by Vokinger and Kesselheim 
[11] as well as changes in public budget expenditures or 
in reimbursement policy. Changes in pricing could also 
result in fluctuations in expenditures. In most cases, after 
the initial approval of the drug, some new clinical data 
regarding drug efficacy would emerge and could influence 
reimbursement decisions. Although the Committee of 
Human Medicinal Products does not have any direct 
influence on prising policy in European Union (EU) 
member states, the type of approval could be considered 
in the decision-making process [5]. Additionally, in this 
study, we focused on the analysis of growing expenditures 
in relation to growing GDP without considering the 
effect of various factors on the expenditures to reveal the 
burden of oncology orphan drugs on the public budget. 
Public expenditures were significantly correlated with 
the total GDP but not with GDP per capita or the share 
of reimbursed oncology orphan drugs, which might 
indicate that the reimbursement of oncology orphan 
drugs could be associated with the general size of country 
economics rather than the welfare of its citizens. This 
could result from a policy that is implemented by many 
countries, namely, to reduce expenses on public health 
to the country’s GDP and not GDP per capita. The most 
informative correlation between GDP per capita and 
expenditures per capita was moderate in size, however 
statically insignificant.
To our knowledge, this is the first study to summarise 
HTA decision making regarding oncology orphan 
drugs in EU countries from the CEE region, as well as 
to analyse the dynamics of public expenditures on the 
reimbursement of those drugs in relation to the GDP and 
GDP per capita.
We were not able to collect relevant data for Slovenia, 
which is a limitation of the study. In addition, we used 
the kappa coefficient to analyse the agreement between 
recommendations and reimbursement status. However, 
the kappa coefficient of agreement could be calculated 
only for the countries that issued both positive and 
negative recommendations to provide some insight into 
the functioning of the reimbursement policy based on 
HTA-assessed drugs. Moreover, the coefficient might 
have been affected by the levels of analysed variables, 
and thus it can be treated as a descriptive rather than 
inferential statistics. As in other statistical tests, only 
cases (drugs) with both the recommendation and 
reimbursement status available were analysed, which 
resulted in different sets of drugs used to calculate 
kappa coefficients in different countries, this approach is 
however appropriate as using in analysis drugs that were 
not even considered for heath technology assessment 
could introduce bias into the analysis. Also, we observed 
that most kappa coefficients in this study were equal 
to 1. This could result from the fact that the countries 
significantly differed in terms of HTA processes, 
which translates into a considerable discrepancy in the 
shares of positive and negative recommendations. In 
some countries, advisory bodies issued only positive 
recommendations.
Another limitation is that the study focused on a set of 
oncology orphan drugs only in one year. Further research 
is needed to compare oncology orphan drugs to non-
oncology ones (e.g. metabolic) and to analyse costs over 
a longer period.
In order to compare the results of our study, we 
reviewed medical databases to identify other important 
publications on this subject. Our previous study [5] 
analysed the status of all drugs with orphan designation 
and their relation to the type of EMA approval. In 
addition, we showed a significant variation in agreement 
with the reimbursement status of analysed drugs across 
selected European countries. The same list of orphan 
drugs was used in another study [12] that described 
the status of orphan drugs in CEE-EU countries. The 
reimbursement of orphan drugs was assessed without 
describing detailed HTA or public budget issues. Both 
studies showed a significant impact of the type of 
approval and disease on the reimbursement decisions. 
Moreover, they revealed that the shares of reimbursed 
orphan drugs are much higher in Western European than 
CEE-EU countries. In addition, we showed that the type 
of the disease was significantly associated with the type of 
marketing authorisation. We also reported that oncology 
drugs were significantly associated with the chances of 
reimbursement. For example, in Croatia, oncological 
orphan drugs were more than 5 times more likely to be 
reimbursed compared with non-oncology drugs (OR 
5.33; 95% CI 1.31–21.68).
The field of oncology orphan drugs was examined in a 
research by Jarosławski et al. and revealed cost differences 
between oncology orphan drugs targeted at smaller 
populations and those targeted at larger populations 
in the United States [13]. No similar research was 
conducted for Europe. On the other hand Vassel et  al. 
analysed whether children and adolescents with cancer 
benefited from the Orphan Drug Regulation in the EU 
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and showed that only 2% of oncology orphan drugs were 
designed for use by children. The analysis covered the 
period from 8 August 2000 to 10 September 2016 [15].
The subject of oncology orphan drugs is not yet well 
described, especially among CEE countries, which 
struggle with a growing burden of reimbursement for 
the public budget and which need detailed data for 
efficient reimbursement decision making and HTA 
assessment regarding orphan drugs (particularly those 
for oncological diseases).
Conclusions
In Hungary, Latvia, and Slovakia, a positive 
recommendation was associated with a positive 
reimbursement decision, while a negative 
recommendation, with a lack of reimbursement. The 
reimbursement of oncology orphan drugs is associated 
with a growing burden for the public budget, with an 
average 3-year increase in expenses of 68%, as compared 
with an increase of only 8.5% in the total GDP and of 
9.3% in GDP per capita among CEE countries. The 
total expenditures on the reimbursement of oncology 
orphan drugs varied among countries and were highly 
correlated with the total national GDP but not with 
GDP per capita. Expenditures per capita also were not 
significantly correlated with GDP per capita. The highest 
share of drugs with any recommendation was observed 
in Poland, and the lowest, in Latvia and Romania. The 
share of reimbursed drugs was the lowest in Latvia and 
the highest in Poland.
Methods
In a previous study [5] we reviewed the EMA website 
[1] and identified all drugs with orphan designation in 
2017. We also collected data on the type of approval, 
disease, and reimbursement status [4] for Bulgaria, 
Croatia, Czechia, Estonia, Hungary, Latvia, Lithuania, 
Poland, Romania, and Slovakia. For the current study, we 
selected only drugs used in the treatment of oncological 
diseases (38% of all analysed drugs) and performed a 
questionnaire survey among experts from respective 
countries. We collected additional data on total public 
expenditures on the reimbursement of those drugs as 
well as HTA recommendations issued for those drugs 
by reimbursement advisory bodies operating in the 
analysed countries. As the economic burden generated 
for national public payers reflects real cash flows in the 
years 2014 to 2016, no inflation corrections were made. 
Local currency units were converted to euros. The total 
expenditures per year per drug per country included 
the cost of reimbursement, expenditures for individual 
request, and expenditures of partial reimbursement of 
specific drugs with patients’ co-payment. The costs were 
presented from the perspective of health care system; 
no distinction was made on whether the cost of drug 
was totally covered by the public payer or was a patients’ 
co-payment involved. Only budget impact was analysed 
which took into account real cash flows from the public 
payer hence the data has been already corrected for any 
existing risk sharing agreements or drug price differences 
[12]. The correlation between the total cost (as well 
as per capita) and gross domestic product (GDP) and 
GDP per capita was analysed using Pearson’s correlation 
coefficient. Data on GDP in US dollars for each analysed 
year were derived from the World Bank [9] and were 
converted in euro using the following exchange rates: 
0.7536 in 2014, 0.9017 in 2015, and 0.9042 in 2016.
Nominal variables were presented as counts and 
percentages. Cost data were rounded to units in 
euros. The agreement between a reimbursement 
recommendation and status in the CEE countries was 
assessed using the κ coefficient [10]. All κ coefficients 
were supported with 95% confidence intervals (CIs) and 
rounded to 2 decimal places.
Statistical analyses were performed in the JMP® 
software, version 14.2.0 (SAS Institute Inc., 2018, Cary, 
North Carolina, USA).
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